TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06242691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetic
Description: One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetic
Description: One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiemetic
Description: One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
Study: NCT06410885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Anisotropy Measurement Device
Description: The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Anisotropy Measurement Device
Description: The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
Study: NCT05380414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor samples (archival FFPE) and blood samples
Description: Molecular screening
Study: NCT06638996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBG Intervention
Description: 50 mg CBG Administered

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intervention
Description: Participants will be administered a placebo
Study: NCT05682560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RegeneCyte
Description: HPC, Cord Blood

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT06236425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-4101
Description: TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Platinum based chemotherapy
Description: Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
Study: NCT05951751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRI-MOM intervention
Description: The TRI-MOM strategy includes 4 main activities:~1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)~2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests~3. Assessment and treatment of women positive for any of the 3 targeted infections~4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections
Study: NCT06236425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
Study: NCT05083468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR750 tablet
Description: The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
Study: NCT05621655

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.
Study: NCT06614556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants in the training groups performed bilateral hand grip resistance training three times per week for four weeks using a specialized hand-grip kit provided to them. Participants were provided with pictures and instructions for each exercise upon completion of the initial testing (PRE) session. They were asked to perform 12 training sessions (approximately 30-45 mins) over the 4 weeks according to their schedule. Each participant was asked to keep a training log to assist with accountability. Those assigned to the control groups were asked to maintain their normal daily activities throughout the four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants in the training groups performed bilateral hand grip resistance training three times per week for four weeks using a specialized hand-grip kit provided to them. Participants were provided with pictures and instructions for each exercise upon completion of the initial testing (PRE) session. They were asked to perform 12 training sessions (approximately 30-45 mins) over the 4 weeks according to their schedule. Each participant was asked to keep a training log to assist with accountability. Those assigned to the control groups were asked to maintain their normal daily activities throughout the four weeks.
Study: NCT06616636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV
Study: NCT05083468

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
Study: NCT06543043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonrotoclax
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonrotoclax
Description: Administered orally.
Study: NCT05446181

Intervention type: BEHAVIORAL
Intervention: Perioperative delirium
Description: Perioperative delirium

Intervention type: PROCEDURE
Intervention: Hip surgery
Description: Orthopedic hip joint surgery under spinal anesthesia

Intervention type: PROCEDURE
Intervention: Hip surgery
Description: Orthopedic hip joint surgery under spinal anesthesia
Study: NCT06537596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Description: Single administration of 89Zr-TLX300-CDx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Description: Single administration of 89Zr-TLX300-CDx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
Description: Single administration of 89Zr-TLX300-CDx
Study: NCT04766203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment of REDS using a holistic treatment arm
Description: This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
Study: NCT05598385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open cannulation
Description: A small incision is made to access the FA and FA. Afterwards, the incision site is traditionally closed with sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous cannulation
Description: Cannulation is performed through a suture-mediated closure system.
Study: NCT06568484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: CCs (Close Contacts) of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV negative, regardless of latent tuberculosis infection (LTBI) result by TST (tuberculin skin test) or IGRA (interferon-gamma release assay)~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Bedaquiline based on weight and/or age at Enrollment daily for four weeks (28 doses)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid, rifapentine
Description: CCs of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV status negative, regardless of latent tuberculosis infection (LTBI) result (tuberculin skin test \[TST\] or interferon-gamma release assay \[IGRA\])~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~3HP: 3 months of weekly isoniazid (H) and rifapentine (P) (12 doses)~1HP: 1 month of daily isoniazid (H) and rifapentine (P) (28 doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Levofloxacin (LFX) based on weight at Enrollment daily for 6 months (182 doses)
Study: NCT05748665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Using remimazolam for induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate
Description: Using etomidate for induction of general anesthesia
Study: NCT06413212

Intervention type: DIAGNOSTIC_TEST
Intervention: Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.
Description: Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
Study: NCT05548010

Intervention type: OTHER
Intervention: No intervention as this is an observational study
Description: No intervention

Intervention type: OTHER
Intervention: No intervention as this is an observational study
Description: No intervention
Study: NCT05379972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV every 3 weeks starting C2D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV every 3 weeks starting C2D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
Study: NCT05868382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010.4
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010.4
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010.6
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010.6
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010.6
Description: Sterile liquid for injection
Study: NCT04802174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
Study: NCT05227703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-231 15 mg
Description: CVL-231 15 mg, oral (tablet), once per day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Required CVL-231 30 mg
Description: CVL-231 30 mg, oral (tablet), once per day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral (tablet), once per day for 6 weeks
Study: NCT05468463

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Donor Navigator Program
Description: The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Donor Navigator Program
Description: The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
Study: NCT05847283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone priming ovarian stiumulation protocol
Description: Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GnRH antagonist protocol
Description: In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
Study: NCT06150534

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT05273437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System identification experiment for physical activity
Description: The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
Study: NCT06616636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezatapopt
Description: Given orally with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezatapopt
Description: Given orally with food
Study: NCT06594848

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black rice extract
Description: Black rice extract is rich in a specific type of anthocyanins, cyanidin. It has been shown by our group that cyanidin-rich food can have beneficial health effects

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this study is composed by maltodextrin and food colorant
Study: NCT06663358

Intervention type: DRUG
Intervention: Pegunigalsidase-alfa
Description: Administered via intravenous (IV) infusion under conditions of routine clinical care

Intervention type: DRUG
Intervention: Pegunigalsidase-alfa
Description: Administered via intravenous (IV) infusion under conditions of routine clinical care

Intervention type: DRUG
Intervention: Pegunigalsidase-alfa
Description: Administered via intravenous (IV) infusion under conditions of routine clinical care
Study: NCT06669104

Intervention type: DEVICE
Intervention: Medtronic Hugo™ surgical robotic system
Description: undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system
Study: NCT06616636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth
Study: NCT06669104

Intervention type: DEVICE
Intervention: Medtronic Hugo™ surgical robotic system
Description: undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system

Intervention type: DEVICE
Intervention: Medtronic Hugo™ surgical robotic system
Description: undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system
Study: NCT06691308

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: WL276 CAR-T cells
Description: This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses
Study: NCT06692179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orally administered preparation of fecal microbiota (MTP-101P)
Description: As per standard of care, patients will receive MBP and OA the day prior to surgery as well as IV antibiotics at the time of surgery. MTP-101P will be given 48 hours after the administration of the dose of IV antibiotics to avoid the undesired bactericidal effects of antibiotics on the bacterial load from MTP-101P.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.
Study: NCT05837117

Intervention type: BEHAVIORAL
Intervention: Patient's Perspective
Description: Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being